Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or ...
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results